Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC

21:13
 
Share
 

Manage episode 514568035 series 2836664
Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.

Click here to read the full article

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

  continue reading

99 episodes

Artwork
iconShare
 
Manage episode 514568035 series 2836664
Content provided by The Lancet Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Lancet Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.

Click here to read the full article

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

  continue reading

99 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play